TIXiMED Secures FDA IND Approval for Novel TIX100 Oral Antidiabetic Drug
TIXiMED has received Investigational New Drug (IND) approval from the United States Food and Drug Administration for its oral treatment for type 1 diabetes, TIX100, a specific inhibitor of the protein TXNIP.
This approval marks an innovative approach to treating both type 1 (T1D) and type 2 diabetes (T2D) and allows TIXiMED to initiate human clinical trials for TIX100.
Before any new drug can be tested in humans, it must undergo thorough safety assessments. To obtain IND approval, TIX100 completed extensive testing in areas such as toxicology, pharmacokinetics, and safety pharmacology, alongside detailed chemistry, manufacturing, and control (CMC) processes to ensure a high-quality, medical-grade product for the upcoming clinical trial.
The development of TIX100 stems from decades of research identifying TXNIP as a harmful protein in human pancreatic islets. Increased levels of TXNIP are associated with diabetes and play a role in the degeneration of insulin-secreting beta cells.
By inhibiting this protein, TIX100 aims to protect these beta cells and enhance overall islet cell health, as shown in various mouse models and human studies involving T1D. TIX100 is a powerful and specific TXNIP inhibitor, offering a novel mechanism of action compared to existing diabetes medications. It is administered orally and addresses the root causes of the disease, showing promising results in pre-clinical studies for both T1D and T2D.
The approach of targeting TXNIP with TIX100 holds the potential to transform diabetes treatment by preserving the pancreas's ability to produce and secrete insulin.
With the recent FDA IND approval, TIXiMED is set to further investigate the effects of this new therapy in human subjects.
TIXiMED expressed enthusiasm over reaching this crucial milestone in the development of TIX100 and looks forward to commencing its first human study.
